MYnd Analytics to Present at the MicroCap Conference on October 5th in New York City at the Essex House
MISSION VIEJO, CA / ACCESSWIRE / September 28, 2017 / MYnd Analytics, Inc. (MYND), a predictive medicine company that brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing in mental health, announced today that Robin Smith, Chairman of the Board will be presenting at the MicroCap Conference on Thursday, October 5th at 1:00 P.M. ET at the Essex House in New York City.
REGISTRATION FOR INVESTORS
To register, please go to the conference website: microcapconf.com/conferences/new-york-2-2017/, and click ''Investor Registration.''
PARTICIPATING COMPANIES
For the most updated list of companies, please go to the conference website: microcapconf.com/conferences/new-york-2-2017/.
FOR MORE INFORMATION
Please visit: www.microcapconf.com
Or, contact Tony Yu at tony@microcapconf.com
News Compliments of ACCESSWIRE.
About MYnd Analytics
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing. The Company's Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company's original physician developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
Forward-looking Statements
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as MYnd's ability to successfully expand into various market channels, the ability of its products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses and MYnd's ability to expand globally in areas where there is an opportunity to improve treatment in mental health, as well as those risks and uncertainties set forth in MYnd's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Contact:
David Waldman / Natalya Rudman
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: mynd@crescendo-ir.com
SOURCE: MYnd Analytics, Inc.
